A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
Tolerability could decide first-line therapy in EGFRm disease.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Ocular toxicities could be the reason.
The group cans ZW171 after “on-target, off-tumour toxicity”.
